Table 1.
Baseline characteristics.
| Category | A1 (n = 16) | A2 (n = 20) | Total (n = 36) |
|---|---|---|---|
| Withdrew before trial treatment | 0 | 2 (10.0%) | 2 (5.6%) |
| Sex | |||
| Male | 14 (87.5%) | 9 (45.0%) | 23 (63.9%) |
| Female | 2 (12.5%) | 11 (55.0%) | 13 (36.1%) |
| Ethnicity | |||
| White British | 16 (100.0%) | 20 (100.0%) | 36 (100.0%) |
| Age (years)a | 65.0 (59.0-75.3) | 64.5 (53.5-68.0) | 64.5 (56.0-69.3) |
| WHO PS | |||
| 0 | 14 (87.5%) | 16 (80.0%) | 30 (83.3%) |
| 1 | 2 (12.5%) | 4 (20.0%) | 6 (16.7%) |
| Primary tumour location | |||
| Oesophagus | 16 (100.0%) | 0 (0.0%) | 16 (44.4%) |
| Melanoma | 0 (0.0%) | 4 (20.0%) | 4 (11.1%) |
| GI adenocarcinoma | 0 (0.0%) | 3 (15.0%) | 3 (8.3%) |
| Cholangiocarcinoma | 0 (0.0%) | 2 (10.0%) | 2 (5.6%) |
| Oesophageal SCC | 0 (0.0%) | 2 (10.0%) | 2 (5.6%) |
| Sarcoma | 0 (0.0%) | 2 (10.0%) | 2 (5.6%) |
| Urothelial Cancer | 0 (0.0%) | 2 (10.0%) | 2 (5.6%) |
| Ductal Breast Cancer | 0 (0.0%) | 1 (5.0%) | 1 (2.8%) |
| Pancreatic NET | 0 (0.0%) | 1 (5.0%) | 1 (2.8%) |
| Papillary thyroid Cancer | 0 (0.0%) | 1 (5.0%) | 1 (2.8%) |
| Tumour sub-location (A1 only) | |||
| Lower thoracic and abdominal portion | 8 (50.0%) | ||
| Mid thoracic portion | 5 (31.2%) | ||
| Upper thoracic portion | 3 (18.8%) | ||
| Tumour length (cm)a (A1 only) | 5.1 (3.6-8.4) | ||
| Histology (A1 only) | |||
| Adenocarcinoma | 10 (62.5%) | ||
| Squamous cell carcinoma | 6 (37.5%) | ||
| Tumour Grade | |||
| Well differentiated (G1) | 1 (6.2%) | 1 (5.0%) | 2 (5.6%) |
| Moderately differentiated (G2) | 3 (18.8%) | 5 (25.0%) | 8 (22.2%) |
| Poorly differentiated (G3) | 8 (50.0%) | 7 (35.0%) | 15 (41.7%) |
| Unknown or cannot be assessed (GX) | 4 (25.0%) | 7 (35.0%) | 11 (30.6%) |
| Locoregional Disease | |||
| Yes | 13 (81.2%) | 10 (50.0%) | 23 (63.9%) |
| No | 3 (18.8%) | 10 (50.0%) | 13 (36.1%) |
| Distant Metastases | |||
| Yes | 6 (37.5%) | 19 (95.0%) | 25 (69.4%) |
| No | 10 (62.5%) | 1 (5.0%) | 11 (30.6%) |
| Prior Radiotherapy | |||
| Yes | 1 (6.2%) | 8 (40.0%) | 9 (25.0%) |
| No | 15 (93.8%) | 12 (60.0%) | 27 (75.0%) |
| Prior Systematic Treatment | |||
| Yes | 13 (81.2%) | 19 (95.0%) | 32 (88.9%) |
| No | 3 (18.8%) | 1 (5.0%) | 4 (11.1%) |
| Oesophageal Stent (A1 only) | |||
| Yes | 0 (0.0%) | ||
| No | 16 (100.0%) | ||
aData are median (interquartiles).